We retrospectively screened 21,747 consecutive treatment-naïve patients who were diagnosed with lung cancer from August 1, 2018, to March 31, 2020, and submitted samples for molecular detection of ROS1 rearrangements, including next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), and amplification refractory mutation system (ARMS) at various hospitals in Hunan, Hubei, Guangdong, and Zhejiang Provinces in China. The gene discussed is ROS1; the disease is lung cancer.